StreetInsider.com News Articles

uniQure reports early data from AMT-260 epilepsy gene therapy trial

Fri, 19 Jun 2026 07:05:15 -0400

uniQure N.V. (NASDAQ: QURE) released preliminary six-month data from the first cohort of its Phase I/IIa clinical trial of AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy (MTLE), according to a company statement.

As of a May 29, 2026 data cutoff, three of six patients in the low-dose cohort (1x10¹² gc/mL) showed reductions in disabling seizures of between 79% and 100% during months four through six of follow-up. The remaining three patients experienced variable outcomes, ranging from a 33% decrease to a 36% increase in disabling seizures compared to baseline.

No serious adverse events related to AMT-260 or the

uniQure reports early data from AMT-260 epilepsy gene therapy trial

Fri, 19 Jun 2026 07:05:15 -0400

No serious adverse events related to AMT-260 or the

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

Fri, 19 Jun 2026 07:05:00 -0400

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~

LEXINGTON, Mass. and AMSTERDAM, June 19, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced initial six-month follow-up data on the first, low dose cohort of six patients in its ongoing Phase I/IIa trial of an investigational gene therapy candidate, AMT-260, for the treatment of refractory mesial temporal lobe epilepsy (MTLE). The data will

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

Fri, 19 Jun 2026 07:05:00 -0400

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

Fri, 19 Jun 2026 07:05:00 -0400

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

Fri, 19 Jun 2026 07:05:00 -0400

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~

Form 144 uniQure N.V. Filed by: Kapusta Matthew C

Thu, 18 Jun 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260618/26667485.html

Form 144 uniQure N.V. Filed by: Kapusta Matthew C

Thu, 18 Jun 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260618/26667485.html

Barclays Upgrades uniQure BV (QURE) to Overweight Following 78% Gain Yesterday

Thu, 18 Jun 2026 08:11:29 -0400

(Updated - June 18, 2026 8:11 AM EDT)

Barclays analyst Eliana Merle upgraded uniQure BV (NASDAQ: QURE) from Equalweight to Overweight with a price target of $65.00 (from $25.00).

The analyst comments "We adjust our anticipated timing of a Huntington's launch to ~1H27 from ~'31 based on QURE's plans to file in 3Q. We also increase our probability of success in Huntington's to 65% from 35% based on an FDA pathway to accelerated approval per QURE. We also adjust opex to contemplate earlier launch timing (SG&A), as well as a confirmatory trial (R&D). Our DCF model through 2040 uses a 12%

Barclays Upgrades uniQure BV (QURE) to Overweight Following 78% Gain Yesterday

Thu, 18 Jun 2026 08:11:29 -0400

(Updated - June 18, 2026 8:11 AM EDT)

Barclays analyst Eliana Merle upgraded uniQure BV (NASDAQ: QURE) from Equalweight to Overweight with a price target of $65.00 (from $25.00).

Barclays Upgrades uniQure BV (QURE) to Overweight Following 78% Gain Yesterday

Thu, 18 Jun 2026 08:11:29 -0400

(Updated - June 18, 2026 8:11 AM EDT)

Barclays analyst Eliana Merle upgraded uniQure BV (NASDAQ: QURE) from Equalweight to Overweight with a price target of $65.00 (from $25.00).

uniQure BV (QURE) PT Raised to $65 at RBC Capital

Thu, 18 Jun 2026 07:42:12 -0400

RBC Capital analyst Luca Issi raised the price target on uniQure BV (NASDAQ: QURE) to $65.00 (from $35.00) while maintaining a Outperform rating.

H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)

Thu, 18 Jun 2026 06:48:12 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $50.00 price target on uniQure BV (NASDAQ: QURE).

The analyst commented: "On June 17, uniQure announced that, during a recent Type B meeting, the FDA communicated that the 3-year analysis from the Phase 1/2 trial of AMT-130 in Huntington’s disease (HD) would be acceptable as the primary basis of a Biologics License Application (BLA) for accelerated approval, with uniQure intending to submit the BLA in 3Q26. FDA also seeks to align on confirmatory study design prior to BLA submission, including consideration of a concurrent standard-of-care (SoC) control arm instead of a

uniQure BV (QURE) PT Raised to $70 at Leerink

Thu, 18 Jun 2026 06:44:31 -0400

(Updated - June 18, 2026 6:44 AM EDT)

Leerink analyst Joseph Schwartz raised the price target on uniQure BV (NASDAQ: QURE) to $70.00 (from $36.00) while maintaining a Outperform rating.

The analyst commented: "We caught up with QURE management following this morning’s update and are resetting our view of the AMT-130 opportunity after FDA’s reversal, which puts the program largely back to where it should have been before the FDA drama, with a 3Q26 BLA submission now planned and the long-term sham-controlled study overhang removed. See our initial reaction here as well as our thoughts on how the regulatory backdrop was changing

uniQure BV (QURE) PT Raised to $70 at Leerink

Thu, 18 Jun 2026 06:44:31 -0400

(Updated - June 18, 2026 6:44 AM EDT)

Leerink analyst Joseph Schwartz raised the price target on uniQure BV (NASDAQ: QURE) to $70.00 (from $36.00) while maintaining a Outperform rating.

uniQure BV (QURE) PT Raised to $70 at Leerink

Thu, 18 Jun 2026 06:44:31 -0400

(Updated - June 18, 2026 6:44 AM EDT)

Leerink analyst Joseph Schwartz raised the price target on uniQure BV (NASDAQ: QURE) to $70.00 (from $36.00) while maintaining a Outperform rating.

Form 144 uniQure N.V. Filed by: Kapusta Matthew C

Wed, 17 Jun 2026 20:07:00 -0400

si-local-file:///var/storage/secattach/20260617/26661490.html

Form 144 uniQure N.V. Filed by: Kapusta Matthew C

Wed, 17 Jun 2026 20:07:00 -0400

si-local-file:///var/storage/secattach/20260617/26661490.html

Form 4 uniQure N.V. For: Jun 15 Filed by: Balachandran Madhavan

Wed, 17 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260617/26660833.html

Form 4 uniQure N.V. For: Jun 15 Filed by: Balachandran Madhavan

Wed, 17 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260617/26660833.html

Form 4 uniQure N.V. For: Jun 15 Filed by: Potts Jeannette

Wed, 17 Jun 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260617/26660750.html

Form 4 uniQure N.V. For: Jun 15 Filed by: Potts Jeannette

Wed, 17 Jun 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260617/26660750.html

Form 144 uniQure N.V. Filed by: Kaye Jack

Wed, 17 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260617/26660476.html

Form 144 uniQure N.V. Filed by: Kaye Jack

Wed, 17 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260617/26660476.html

Form 144 uniQure N.V. Filed by: Balachandran Madhavan

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659788.html